Diabetes Care Devices Market Size, Share, Growth, and Industry Analysis, By Type (Blood Glucose Monitoring Devices, Insulin Delivery Devices), By Application (Medical Care, Personal Care, Clinic), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

DIABETES CARE DEVICES MARKET OVERVIEW

The global diabetes care devices market size is USD 12.85 Billion in 2026 and is projected to reach USD 21.14 Billion by 2035, growing at a CAGR of 5.69% from 2026 to 2035.

The diabetes care devices market encompasses blood glucose monitoring devices, continuous glucose monitoring systems, insulin pumps, insulin pens, and automated insulin delivery technologies. Global diabetes prevalence reached 589 million adults in 2024, strengthening demand for accessible monitoring and treatment equipment. Approximately 252 million adults remain undiagnosed, highlighting opportunities for improved screening and diagnostic accessibility. The diabetes care devices market is transitioning toward connected sensors, predictive glucose alerts, wearable insulin delivery systems, and smartphone-integrated platforms. Manufacturers are prioritizing measurement accuracy, patient convenience, clinical interoperability, and automated treatment adjustments. Expanding diabetes management programs continue to support device adoption across healthcare settings worldwide.

The United States diabetes care devices market benefits from established healthcare infrastructure, specialized endocrinology services, and widespread access to advanced medical technology. Continuous glucose monitoring systems are increasingly integrated into diabetes treatment programs, while automated insulin delivery platforms support personalized therapy. Healthcare providers emphasize remote patient monitoring, electronic health record integration, and improved treatment adherence. Insurance coverage policies influence device selection and accessibility across different patient populations. Manufacturers continue introducing compact sensors, connected insulin pumps, and user-friendly monitoring applications. Growing emphasis on preventive healthcare, home-based diabetes management, and technology-enabled clinical decisions supports continued development throughout the United States market.

KEY FINDINGS

LATEST TRENDS

The diabetes care devices market is experiencing substantial technological transformation as manufacturers prioritize continuous glucose monitoring, automated insulin delivery, and connected healthcare platforms. Wearable glucose sensors increasingly replace conventional testing in suitable patient populations because they provide continuous information about glucose fluctuations. Manufacturers are developing smaller sensors, longer wear durations, improved accuracy, and simplified application procedures. Smartphone integration enables users to review glucose trends, receive alerts, and share information with healthcare professionals.

Approximately 589 million adults worldwide were living with diabetes in 2024, emphasizing the importance of accessible diabetes management technology. This growing clinical requirement encourages manufacturers to develop monitoring solutions suitable for hospitals, clinics, and home environments. Artificial intelligence and predictive analytics are becoming important components of diabetes management systems. Algorithms interpret glucose patterns and support automated insulin adjustments in compatible devices. Integrated monitoring platforms improve treatment coordination and reduce dependence on manual recordkeeping.

MARKET DYNAMICS

DRIVER

Increasing diabetes prevalence and adoption of continuous glucose monitoring technologies.

The principal driver of the diabetes care devices market is the increasing requirement for accurate, convenient, and continuous diabetes management. Global diabetes prevalence reached 589 million adults in 2024, creating substantial clinical demand for glucose testing equipment, insulin delivery systems, and connected monitoring technologies. Healthcare professionals increasingly recommend continuous glucose monitoring for eligible patients requiring detailed glucose information. These systems provide glucose trend visibility and support earlier identification of potentially dangerous fluctuations. Automated insulin delivery technologies also reduce manual treatment demands for suitable insulin users.

Drivers Impact Analysis*

RESTRAINT

Limited affordability and uneven reimbursement for advanced diabetes devices.

High acquisition and ongoing operating costs remain important restraints affecting the diabetes care devices market. Continuous glucose monitoring systems require periodic sensor replacement, while insulin pumps may involve consumables, accessories, and specialized training. Although advanced devices offer clinical benefits for eligible users, financial barriers can limit accessibility in healthcare systems with restricted reimbursement. Insurance eligibility criteria also vary according to treatment requirements, device classification, and local healthcare policies. Patients without comprehensive coverage may continue relying on conventional blood glucose meters.

Restraints Impact Analysis*

Expansion of connected diabetes management across underserved healthcare markets.

Opportunity

The diabetes care devices market offers substantial opportunities through improved access to monitoring equipment and connected treatment technologies. Approximately 252 million adults living with diabetes worldwide were unaware of their condition in 2024, highlighting the importance of stronger screening infrastructure and earlier diagnosis. Manufacturers can address this requirement through affordable glucose meters, accessible testing supplies, and simplified digital monitoring solutions. Emerging healthcare systems are investing in chronic disease management, creating opportunities for device distribution partnerships and clinical training programs. Connected glucose monitoring platforms can support remote consultations and improve communication between patients and healthcare professionals.

Maintaining device accuracy, cybersecurity, and compatibility across connected treatment systems.

Challenge

The diabetes care devices market faces significant challenges involving clinical reliability, software integration, and patient safety. Glucose monitoring systems must maintain dependable performance under changing physiological and environmental conditions. Inaccurate readings can influence treatment decisions, making product validation and quality control essential. Connected insulin delivery systems introduce additional complexity because sensors, algorithms, and infusion devices must operate reliably together. Cybersecurity protection is increasingly important as diabetes management platforms exchange sensitive health information through smartphones and cloud-connected applications.

•   
•   
  

  Download Free Sample to learn more about this report

    

DIABETES CARE DEVICES MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into blood glucose monitoring devices and insulin delivery devices.

• Blood Glucose Monitoring Devices: Blood glucose monitoring devices account for 62% of the diabetes care devices market, making them the leading product category. This segment includes conventional blood glucose meters, test strips, lancets, continuous glucose monitoring sensors, transmitters, and compatible monitoring applications. Conventional meters remain important for routine testing, confirmation of sensor readings, and diabetes management where continuous monitoring is unavailable. Continuous glucose monitoring systems provide glucose trend information and alerts that support more informed treatment decisions.

• Insulin Delivery Devices: Insulin delivery devices represent a 38% share of the diabetes care devices market. This category includes insulin pens, insulin pumps, infusion sets, wearable patch pumps, and automated insulin delivery systems. These products support patients requiring insulin treatment and provide alternatives to conventional injection methods. Smart insulin pens can record dosing information, while connected pumps can integrate with compatible glucose monitoring systems. Automated insulin delivery platforms use sensor information and control algorithms to adjust insulin administration within prescribed operating parameters.

By Application

Based on Application, the global market can be categorized into medical care, personal care, and clinic.

• Medical Care: Medical care accounts for a 34% share of the diabetes care devices market. This application includes diabetes management in hospitals, specialized treatment centers, and other institutional healthcare environments. Medical professionals use glucose monitoring devices to support treatment decisions, evaluate glucose fluctuations, and manage patients requiring insulin therapy. Hospital diabetes management involves careful monitoring of patients experiencing acute illness, surgical procedures, or complex metabolic conditions. Device selection depends on clinical protocols, measurement reliability, compatibility, and staff training requirements. Healthcare institutions increasingly evaluate connected monitoring platforms to improve information availability and treatment coordination.

• Personal Care: Personal care leads the diabetes care devices market with a 48% share. This segment includes home glucose testing, wearable continuous glucose monitoring, insulin pens, and compatible personal insulin delivery systems. Patients increasingly prefer devices that support independent diabetes management while maintaining communication with healthcare professionals. Smartphone applications provide access to glucose trends, alerts, treatment records, and information sharing. Continuous monitoring can reduce reliance on repeated fingerstick testing for many eligible users, although conventional testing remains necessary in certain circumstances.

• Clinic: Clinics account for an 18% share of the diabetes care devices market. This segment includes outpatient diabetes centers, endocrinology practices, primary care clinics, and specialized metabolic health facilities. Healthcare professionals use glucose monitoring systems to assess treatment effectiveness, identify glucose patterns, and educate patients about disease management. Clinics also provide device demonstrations, sensor placement assistance, insulin pump training, and ongoing treatment adjustments. Professional continuous glucose monitoring can provide useful glucose information during defined assessment periods.

•   
•   
  Download Free Sample to learn more about this report

    

DIABETES CARE DEVICES MARKET REGIONAL INSIGHTS

• North America

North America holds a 38% share of the global diabetes care devices market, supported by advanced medical infrastructure, established diabetes management programs, and widespread availability of connected monitoring technologies. The United States represents the principal regional market, with Canada contributing through publicly funded healthcare services and specialized diabetes treatment programs. This substantial patient population creates continuing demand for blood glucose meters, continuous glucose monitoring sensors, insulin pens, and automated insulin delivery systems.

• Europe

Europe represents a 27% share of the diabetes care devices market, reflecting established healthcare systems, specialist diabetes services, and increasing adoption of connected monitoring technologies. Germany, France, the United Kingdom, Italy, and Spain represent important national markets for glucose monitoring and insulin delivery equipment. Approximately 66 million adults were living with diabetes across the broader European diabetes surveillance region in 2024.

• Asia-Pacific

Asia Pacific accounts for a 24% share of the global diabetes care devices market. The region contains substantial diabetes patient populations, expanding healthcare infrastructure, and increasing demand for affordable monitoring equipment. China, India, Japan, South Korea, and Australia represent important markets with different purchasing patterns and clinical requirements. India had approximately 89.8 million adults living with diabetes in 2024, demonstrating the substantial need for accessible diagnosis and long-term disease management.

• Middle East & Africa

The Middle East & Africa represents a 7% share of the diabetes care devices market. Regional demand is influenced by increasing diabetes prevalence, healthcare infrastructure investment, and expanding awareness of chronic disease complications. Saudi Arabia, the United Arab Emirates, South Africa, and Egypt represent important markets for glucose monitoring and diabetes treatment equipment. The broader Middle East and North Africa diabetes surveillance region recorded approximately 85 million adults living with diabetes in 2024.

• Rest of the World

The rest of the world accounts for a 4% share of the global diabetes care devices market, covering markets outside the defined North American, European, Asia Pacific, and Middle East & Africa commercial regions. Latin American countries contribute substantially to this category, with Brazil, Mexico, Argentina, and Chile representing important healthcare markets. Approximately 35 million adults were living with diabetes across the South and Central America diabetes surveillance region in 2024.

KEY INDUSTRY PLAYERS

The diabetes care devices market is highly competitive, with leading companies focusing on advanced glucose monitoring, insulin delivery, and diabetes management technologies. Key industry players include Abbott Laboratories, Medtronic plc, Dexcom, Inc., F. Hoffmann-La Roche Ltd., and Insulet Corporation. These companies are investing in product innovation, continuous glucose monitoring systems, connected devices, and digital health solutions to strengthen their market presence. Strategic partnerships, product launches, and technological advancements are further shaping the competitive landscape.

List of Top Diabetes Care Devices Companies

• Roche Diagnostic
• LifeScanInc
• Bayer HealthCare
• Abbott Laboratories
• Johnson and Johnson
• Dickinson and Company
• Acon Laboratories, Inc
• Ypsomed AG
• Novo Nordisk A/S
• Medtronic plc
• ARKRAY Inc
• Terumo Corporation
• Dexcom
• Sanofi

LEADER INSIGHTS

• Dexcom: Jake Leach, President and CEO, highlighted the growing opportunity for continuous glucose monitoring among people with type 2 diabetes who do not use insulin. He emphasized that stronger clinical evidence and broader support from healthcare providers and payers could accelerate global adoption of CGM technology. (Published: October 14, 2026 | Source: https://investors.dexcom.com)

• Medtronic plc: Que Dallara, Executive Vice President and President of Medtronic Diabetes, emphasized that expanding Medicare access and increasing treatment flexibility are important factors supporting automated insulin delivery adoption. Her comments highlight how broader insurance coverage, additional sensor choices, and regulatory clearances can improve patient access and create opportunities for advanced diabetes management technologies. (Published: February 2, 2026 | Source: https://news.medtronic.com)

• Abbott Laboratories: Jared Watkin, then Senior Vice President of Diabetes Care, emphasized that affordability and accessibility are essential to increasing continuous glucose monitoring adoption. His comments highlighted Abbott's focus on reducing cost barriers through its FreeStyle Libre portfolio, demonstrating how accessible glucose monitoring solutions can support wider patient adoption and long-term diabetes care market expansion. (Published: October 2023 | Source: https://www.abbott.com)

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment opportunities within the diabetes care devices market increasingly concentrate on connected monitoring, automated insulin delivery, and accessible healthcare technology. Approximately 589 million adults worldwide were living with diabetes in 2024, supporting long-term demand for monitoring and treatment infrastructure. Manufacturers are investing in sensor accuracy, device miniaturization, algorithm development, and interoperability. Healthcare organizations are expanding remote patient monitoring capabilities and digital treatment programs. Emerging markets present opportunities for affordable glucose testing equipment and localized distribution networks. Strategic partnerships between sensor manufacturers, insulin pump developers, and healthcare providers can accelerate product integration. Clinical validation and reimbursement access remain essential investment considerations.

NEW PRODUCT DEVELOPMENT

New product development in the diabetes care devices market focuses on improving monitoring accuracy, treatment automation, and patient convenience. Dexcom received United States regulatory clearance for its G7 15 Day continuous glucose monitoring system in April 2025, introducing extended sensor wear for eligible adults. Abbott advanced dual-analyte monitoring technology is capable of continuously measuring glucose and ketones through a wearable sensor. Manufacturers are developing compact monitoring devices, simplified application mechanisms, and enhanced wireless connectivity. Automated insulin delivery platforms increasingly integrate sensor information with dosing algorithms. Product development also emphasizes cybersecurity, clinical interoperability, smartphone applications, and improved accessibility for patients managing diabetes outside traditional healthcare facilities.

RECENT DEVELOPMENTS

• May 2026 – Abbott advances continuous glucose and ketone monitoring through integrated wearable technology. Abbott secured European regulatory certification for Libre Duo technology, combining continuous glucose and ketone sensing to support diabetes management and earlier identification of rising ketones.

• June 2026 – Insulet expands automated insulin delivery capabilities through enhanced algorithms and sensor compatibility. Insulet introduced enhanced Omnipod 5 algorithms and expanded Libre 3 Plus compatibility, supporting personalized glucose targets, improved automated operation, and broader monitoring device choice.

REPORT COVERAGE

The diabetes care devices market report examines product technologies, application demand, regional adoption patterns, competitive positioning, and industry developments. Coverage includes blood glucose monitoring devices and insulin delivery devices, with category shares of 62% and 38%, respectively. Application analysis evaluates medical care, personal care, and clinics, while regional assessment covers North America, Europe, Asia Pacific, the Middle East & Africa, and the rest of the world. The report addresses continuous glucose monitoring, automated insulin delivery, digital connectivity, reimbursement conditions, and clinical accessibility. Competitive coverage evaluates established manufacturers, technology partnerships, regulatory developments, product innovation, and emerging opportunities in diabetes management.